Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Marketwired
166 Leser
Artikel bewerten:
(0)

Bradmer Announces Third Quarter Operational and Financial Results

Finanznachrichten News

TORONTO, ONTARIO -- (Marketwired) -- 11/05/13 -- Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") (TSX VENTURE: BMR.H) today announced its third quarter 2013 operational and financial results.

Operational Highlights

The directors and officers of Bradmer continue to seek out new opportunities in the ongoing process of identifying and completing an appropriate business transaction with a view to creating value for Bradmer and its shareholders. During the last quarter, the Company has been actively involved in ongoing discussions with various parties in connection with potential investment and/or merger opportunities.

Financial Results

Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").

For the three months ended September 30, 2013, we recorded a net loss of $47,000 or $0.002 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to a net loss of $77,000 or $0.004 per common share for the quarter ended September 30, 2012 based on the weighted average outstanding shares of 19,659,726.

General and administrative expenses were $39,000 in the three months ended September 30, 2013 compared to $62,000 in the same quarter of the prior year. Major expenses in 2013 consisted of consulting fees of $18,000, legal fees of $7,000, audit fees of $4,000 and directors' and officers' liability insurance premiums of $4,000. In 2012, major expenses included consulting fees of $18,000, insurance premiums of $15,000, legal fees of $9,000 and audit fees of $6,000.

The $8,000 foreign exchange gain in the third quarter of 2013 was lower than the $15,000 foreign exchange loss in the same quarter of 2012.

For the nine months ended September 30, 2013, we recorded a net loss of $109,000 or $0.006 per common share based on the weighted average outstanding shares of 19,659,726 during the nine month period, compared to a net loss of $186,000 or $0.009 per common share for the nine months ended September 30, 2012 based on the weighted average outstanding shares of 19,659,726.

General and administrative expenses were $126,000 in the nine months ended September 30, 2013 compared to $172,000 in the same period of the prior year. Major expenses in 2013 consisted of consulting fees of $53,000, legal fees of $25,000, insurance premiums of $15,000, audit fees of $13,000 and transfer agent and stock exchange listing fees of 11,000. Major expenses in 2012 consisted of consulting fees of $55,000, insurance premiums of $44,000, legal fees of $30,000, audit fees of $20,000 and transfer agent and stock exchange listing fees of $18,000. Limits on the directors' and officers' liability insurance were reduced from $5,000,000 to $2,000,000 accounting for the reduction in premiums in 2013.

A $17,000 foreign exchange gain in the current nine-month period contrasted with a $15,000 loss in the prior year period.

Our operational activities for the nine months ended September 30, 2013 were financed by cash on hand. At September 30, 2013, we had working capital of $826,000, compared to $971,000 at December 31, 2012. We had available cash of $837,000 at September 30, 2013, compared to cash of $991,000 at December 31, 2012. The decrease was primarily due to the $109,000 operating loss incurred in the first nine months of 2013 and the foreign currency translation adjustments.

As at November 5, 2013 and September 30, 2013, the Company had 19,659,726 common shares and options to purchase 1,950,000 common shares outstanding.

Bradmer Pharmaceuticals Inc.

Paul Van Damme, Chief Financial Officer

Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at www.sedar.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Bradmer's common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this news release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Financial Position
As at
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                              September 30,    December 31,
                                                       2013            2012
----------------------------------------------------------------------------
                                                                   (audited)
Assets

Current assets
  Cash                                       $      837,316  $      990,759
  Amounts receivable                                  3,652           2,861
  Prepaid expenses                                    5,873           5,287
----------------------------------------------------------------------------

Total assets                                 $      846,841  $      998,907
----------------------------------------------------------------------------

Liabilities and Shareholders' Equity

Current liabilities
  Accounts payable and accrued liabilities   $       20,149  $       27,440
----------------------------------------------------------------------------

Shareholders' Equity
  Share capital                                   2,219,979       2,307,972
  Contributed surplus                             2,453,145       2,550,381
  Accumulated other comprehensive loss               (7,180)       (156,515)
  Deficit                                        (3,839,252)     (3,730,371)
----------------------------------------------------------------------------

Total shareholders' equity                          826,692         971,467
----------------------------------------------------------------------------

Total liabilities and shareholders' equity   $      846,841  $      998,907
----------------------------------------------------------------------------

Approved on behalf of the Board:

Dale Boden, Director

Charles Lilly, Director

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Comprehensive (Income)/Loss
For the nine months ended September 30, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                             Nine Months Ended        Three Months Ended
                               September 30              September 30
                                2013         2012         2013         2012
----------------------------------------------------------------------------


Expenses
  General and
   administrative        $   125,701  $   171,630  $    39,124  $    62,370
----------------------------------------------------------------------------

                             125,701      171,630       39,124       62,370
----------------------------------------------------------------------------

Other Income
  Interest                       (56)        (314)         (54)        (113)
  Foreign exchange
   (gain)/loss               (16,664)      14,795        7,547       15,075
----------------------------------------------------------------------------

                             (16,820)      14,481        7,493       14,962
----------------------------------------------------------------------------

Loss for the period      $   108,881  $   186,111  $    46,618  $    77,332

Other comprehensive
 (income)/loss              (149,335)     126,892       63,052      132,102
----------------------------------------------------------------------------

Comprehensive
 (income)/loss for the
 period                  $   (40,454)    $313,003  $   109,670  $   209,434
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Loss per share
Basic and diluted        $     0.006  $     0.009  $     0.002  $     0.004
----------------------------------------------------------------------------

Weighted average number
 of shares outstanding    19,659,726   19,659,726   19,659,726   19,659,726
----------------------------------------------------------------------------

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Changes in Shareholders' Equity
For the nine months ended September 30, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------

                                 Share capital
                           -------------------------
                              Number of                         Contributed
                                 shares      Amount   Warrants      surplus
----------------------------------------------------------------------------

Balance, January 1, 2012     19,659,726 $ 2,257,819  $  23,255  $ 2,471,705

Expiry of warrants                    -           -    (23,255)      23,255

Foreign currency
 translation adjustment               -      77,619          -       85,770

Loss for the period                   -           -          -            -
----------------------------------------------------------------------------

Balance, September 30, 2012  19,659,726 $ 2,335,438  $       -  $ 2,580,730
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Balance, January 1, 2013     19,659,726 $ 2,307,972  $       -  $ 2,550,381

Foreign currency
 translation adjustment               -     (87,993)         -      (97,236)

Loss for the period                   -           -          -            -
----------------------------------------------------------------------------

Balance, September 30, 2013  19,659,726 $ 2,219,979  $       -  $ 2,453,145
----------------------------------------------------------------------------
----------------------------------------------------------------------------


BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Changes in Shareholders' Equity
For the nine months ended September 30, 2013 and 2012
(All amounts expressed in United States dollars)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                               Accumulated
                                     Other                            Total

                             Comprehensive                    Shareholders'
                             Income/(Loss)         Deficit           equity
----------------------------------------------------------------------------

Balance, January 1, 2012   $       (75,798) $   (3,511,621) $     1,165,360

Expiry of warrants                       -               -                -

Foreign currency
 translation adjustment           (126,892)              -           36,497

Loss for the period                      -        (186,111)        (186,111)
----------------------------------------------------------------------------

Balance, September 30, 2012$      (202,690) $   (3,697,732) $     1,015,746
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Balance, January 1, 2013   $      (156,515) $   (3,730,371) $       971,467

Foreign currency
 translation adjustment            149,335               -          (35,894)

Loss for the period                      -        (108,881)        (108,881)
----------------------------------------------------------------------------

Balance, September 30, 2013$        (7,180) $   (3,839,252) $       826,692
----------------------------------------------------------------------------
----------------------------------------------------------------------------

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Cash Flows
For the nine months ended September 30, 2013 and 2012
(All amounts expressed in United States dollars)
                                                        2013           2012
----------------------------------------------------------------------------


Cash flows from operating activities
  Loss for the period                          $    (108,881) $    (186,111)
  Adjustments for:
    Foreign exchange (gain)/loss                     (35,894)        36,497
----------------------------------------------------------------------------

                                                    (144,775)      (149,614)
  Change in non-cash operating items
    Amounts receivable                                  (791)        (2,477)
    Prepaid expenses                                    (586)        (1,387)
    Accounts payable and accrued expenses             (7,291)        (8,788)
----------------------------------------------------------------------------

Decrease in cash                                    (153,443)      (162,266)

Cash at beginning of period                          990,759      1,192,307
----------------------------------------------------------------------------

Cash at end of period                          $     837,316  $   1,030,041
----------------------------------------------------------------------------
----------------------------------------------------------------------------

Contacts:
Bradmer Pharmaceuticals Inc.
Paul Van Damme
Chief Financial Officer
1.647.629.0136
pvandamme@bradmerpharma.com

© 2013 Marketwired
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.